Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1

Hosanagar, Avinash; Cusimano, Joseph; Radhakrishnan, Rajiv

doi:10.4088/jcp.20ac13786

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lucke-Wold B MedPress Publications LLC and tau hyperphosphorylation and accumulation [6]. Psychedelic medications are promising therapeutics in CTE for their ability to treat neuropsychiatric deficits and ability to promote neuroplasticity and suppress neuroinflammation and neurodegeneration [73][74][75][76][77][78][79][80][81][82][83][84].…”

Section: Medpress Psychiatry and Behavioral Sciencesmentioning

confidence: 99%

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

Fusco¹,

Olowofela²,

Dagra³

et al. 2022

MPPBS

View full text Add to dashboard Cite

show abstract

Section: Medpress Psychiatry and Behavioral Sciencesmentioning

confidence: 99%

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

Fusco¹,

Olowofela²,

Dagra³

et al. 2022

MPPBS

View full text Add to dashboard Cite

show abstract

“…While the use of the term "psychedelic" has no official definition, it typically refers to a drug that is able to alter perception, thoughts, feelings and consciousness in humans (Hosanagar et al, 2021). Psychedelic drugs are commonly categorized as either "classical" or "atypical" (Kamal et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

Wang,

Kim,

Aleksandrova

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. Psilocybin is most commonly found in different species of mushroom; however, the literature on mushroom and fungus extracts with potential antidepressant activity extends well beyond just psilocybin-containing mushrooms, and includes both psychedelic and non-psychedelic species. In the current review, we systematically review the preclinical literature on mushroom and fungus extracts, and their effects of animal models of depression and tests of antidepressant activity. The PICO structure, PRISMA checklist and the Cochrane Handbook for systematic reviews of intervention were used to guide the search strategy. A scoping search was conducted in electronic databases PubMed, CINAHL, Embase and Web of Science. The literature search identified 50 relevant and suitable published studies. These included 19 different species of mushrooms, as well as seven different species of other fungi. Nearly all studies reported antidepressant-like effects of treatment with extracts. Treatments were most commonly delivered orally, in both acute and chronically administered studies to predominantly male rodents. Multiple animal models of depression were used, the most common being unpredictable chronic mild stress, while the tail suspension test and forced swim test were most frequently used as standalone antidepressant screens. Details on each experiment with mushroom and fungus species are discussed in detail, while an evaluation is provided of the strengths and weaknesses of these studies.

show abstract

Perspectives and preliminary experiences of psychedelics for the treatment of eating disorders: A systematic scoping review

Cuerva,

Spirou,

Cuerva

et al. 2024

Euro Eating Disorders Rev

View full text Add to dashboard Cite

ObjectiveResearch regarding the therapeutic application of psychedelics and psychedelic‐assisted psychotherapy in the treatment of eating disorders (EDs) has begun to emerge. This systematic scoping review aimed to map and synthesise the existing evidence regarding the participant reported efficacy and perspectives concerning psychedelics in the treatment of EDs, and to identify significant research gaps.MethodA systematic search was undertaken across several databases in accordance with Preferred Reporting Items for Systematic reviews and Meta‐Analyses extension for Scoping Reviews guidelines.Results1290 publications were identified, 1135 after duplicates removed, with 17 meeting full‐eligibility criteria. Overall, findings suggested that most participants reported experiencing a meaningful reduction in their ED symptoms and having positive experiences or an openness to explore psychedelics as a treatment for ED symptoms, although some noted concerns of adverse effects and the importance of having psychological support to increase safety and efficacy.ConclusionsWhile preliminary research suggests psychedelics and psychedelic‐assisted psychotherapy may be a viable treatment option for ED symptoms, further research with more robust research designs is required to increase confidence in its efficacy, generalisability, and safety as a therapeutic medium.

show abstract

Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1

Cited by 7 publications

References 0 publications

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

Management of Neuropsychiatric Symptoms for Chronic Traumatic Encephalopathy

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity

Perspectives and preliminary experiences of psychedelics for the treatment of eating disorders: A systematic scoping review

Contact Info

Product

Resources

About